[S-29] Alzheimer's disease up to date

[S-29-1] Aducanumab and immunotherapy for the treatment of AD: what have we learnt from preclinical research?

^○Bussière Thierry¹, Paul Weinreb², Fang Qian², Joe Arndt², Benjamin Smith², Thomas o. Cameron², Blake Pepinsky², Chao Quan², Krishna Praneeth Kilambi² (1.Alzheimer & Dementia Research Unit, Biogen, 2.Biologics Drug Discovery, Biogen)

Principal Scientist and group leader, Lead scientist for the Aducanumab Program, Alzheimer & Dementia Research Unit, Biogen, Cambridge (USA).
PhD in Neurosciences, Lille University, France (1998) - Postdoctoral fellowship with Pr. Patrick Hof, Mount Sinai School of Medicine, New York (1999-2001) - Postdoctoral Scientist with Dr. Dale Schenk, Elan Pharmaceuticals, San Francisco (2001-2005).
Recent publications:
Budd Haeberlein S, O'Gorman J, Chiao P, Bussière T, et al.. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. Journal of Prevention and Alzheimers Disease. 2017;4(4):255-263.
Nobuhara CK., et al., Bussière T., Weinreb PH., Hyman BT., Takeda S. Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. American Journal of Pathology. 2017 Jun;187(6):1399-1412.
Kastanenka KV., Bussière T., Shakerdge N., Qian F., et al.. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. Journal of Neuroscience. 2016 Dec 14;36(50):12549-12558.
Sevigny J., Chiao P., Bussière T., Weinreb PH., et al.. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6.